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Objectives. This study sought to demonstrate the equivalence of
saruplase and streptokinase in terms of 30-day mortality.
Background. The use of thrombolytic agents in the treatment of
acute myocardial infarction is well established and has been
shown to substantially reduce post-myocardial infarction mortal-
ity.
Methods. Three thousand eighty-nine patients with symptoms
compatible with those of acute myocardial infarction for <6 h
entered the study at a total of 104 centers and were randomized to
receive streptokinase (1.5-MU infusion over 60 min) or saruplase
(20-mg bolus and 60-mg infusion over 60 min). In the saruplase
group, a bolus of heparin (5,000 IU) was administered before
saruplase, and a corresponding blinded double-dummy placebo
bolus was administered before streptokinase. All patients received
intravenous heparin infusions for >224 h starting 30 min after the
end of the thrombolytic infusions; the infusions were titrated to
maintain an activated partial thromboplastin time at 1.5 to 2.5
times that of normal.
Results. Death of any cause up to 30 days after randomization
occurred in 88 (5.7%) of 1,542 patients randomized to receive
saruplase and 104 (6.7%) of 1,547 patients randomized to receive
streptokinase (odds ratio 0.84, p < 0.01 for equivalence). Hemor-
rhagic strokes occurred more often in patients receiving saruplase
(0.9% vs. 0.3%), whereas thromboembolic strokes were more
prevalent in the streptokinase-treated patients (0.5% vs. 1.0%).
The rate of bleeding was similar in the two treatment groups
(10.4% vs. 10.9%). Hypotension and cardiogenic shock occurred
less frequently in the saruplase group. Reinfarction rates were
similar.
Conclusions. Saruplase is a clinically safe and effective throm-
bolytic medication. This profile ranks saruplase favorably among
the currently available thrombolytic agents.
(J Am Coll Cardiol 1998;31:487–93)
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The use of thrombolytic agents in the treatment of acute
myocardial infarction is well established (1); the most widely
used thrombolytic agent in Europe is streptokinase. Newer
thrombolytic agents have been developed based on endoge-
nous plasminogen activators, including tissue-type plasmino-
gen activator (t-PA [e.g., alteplase]) and urokinase-type plas-
minogen activator (u-PA [e.g., saruplase]). Saruplase, a
recombinant, unglycosylated, human, single-chain u-PA is a
protein of known amino acid sequence that is produced
through the use of genetically transformed Escherichia coli
bacteria (2). Because saruplase has an amino acid structure
that is identical to that of endogenous u-PA, there should be
no risk of allergic reactions or antigenicity, as occurs with
xenobiotic compounds like streptokinase. Saruplase has been
shown to be more efficacious than streptokinase in restoring
coronary artery patency (3). Although patency trials may
demonstrate superiority in terms of clot lysis times and resto-
ration of perfusion of the ischemic myocardium, because of
their limited statistical power they cannot confirm differences
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in survival rates. Conventional mortality trials require many
tens of thousands of patients to demonstrate the superiority of
one thrombolytic agent over another.
In the present study, we took a novel approach to demon-
strate the efficacy of a new agent by demonstrating that infarct
survival is at least as good as that with a current standard. The
results of a similar trial designed to show the equivalence of
reteplase with streptokinase that began in August 1993 have
been recently reported (4).
Methods
Study organization. A total of 104 centers in 10 West
European countries, Russia and Israel participated in the study
(see Appendix). Ethics committee appraisal of the protocol
was obtained for all centers involved from the hospital or
regional or national institutional review board. International
logistics coordination was performed by the sponsor
(Gru¨nenthal GmbH). An international steering committee
met at regular intervals to review the course of the study. The
study was conducted according to good clinical practice guide-
lines (5), and source data auditing was routinely performed.
Patients. Male or female patients .20 years old presenting
to a study center within 6 h after the onset of acute myocardial
infarction symptoms were screened for entry into the study.
Eligible patients exhibited nitrate-resistant chest pain lasting
for $30 min, with ST segment elevation .0.1 mV in two or
more frontal plane leads or .0.2 mV in two or more precordial
leads. Exclusion criteria included severe hypertension (systolic
blood pressure .200 mm Hg or diastolic blood pressure
.100 mm Hg on admission or hypertensive retinopathy grade
III or IV) or known intracranial, gastrointestinal, clotting,
hepatic, pulmonary, renal, urogenital, vascular or other disor-
ders that could increase the risk of bleeding after thrombolysis.
Patients with major trauma or surgical procedures within 1
month were excluded, as were those with malignancy or known
sensitivity to streptokinase or exposure to streptokinase within
the past year or streptococcal infection within the past 3
months. In June 1993 (after ;800 patients had been entered),
the protocol was amended to allow patients .75 years old to
enter the study. All patients gave witnessed or written in-
formed consent.
Randomization and treatment strategy. The investigators
used numbered, prerandomized medication kits in ascending
order. The medication was supplied by Gru¨nenthal GmbH,
Aachen, Germany. Each kit contained either 1) heparin
(5,000 IU for initial intravenous bolus), saruplase (20-mg vial
for intravenous bolus and 60 mg for 60-min intravenous
infusion) and streptokinase placebo, or 2) placebo to heparin
(for initial intravenous bolus), streptokinase (1.5 MU for
60-min intravenous infusion) and saruplase placebo (Fig. 1).
Additional therapy. Oral or intravenous acetylsalicylic acid
(ASA) was administered as a loading dose before thrombolysis
(200 to 400 mg), followed by a daily oral maintenance dose of
$75 mg.
Heparin was administered to all patients for $24 h, starting
as an intravenous infusion 30 min after the end of the
thrombolytic infusions. The starting dose was 15 IU/kg per h,
with dose titration to achieve an activated partial thromboplas-
tin time (aPTT) of 1.5 to 2.5 times the control value.
The use of intravenous nitrates was recommended. All
other medication administered in the hospital, including addi-
tional thrombolytic agents, was permitted if considered neces-
sary and was documented.
Invasive coronary procedures, including percutaneous
transluminal coronary angioplasty (PTCA) and coronary artery
bypass graft surgery (CABG), were permitted at the investiga-
tor’s discretion.
Clinical data, end points and follow-up. The primary end
point was death from any cause at 30 days after the start of
study treatment. Other prospectively defined end points up to
30 days were cerebral events, reinfarction and reintervention,
such as PTCA, CABG or further thrombolytic treatment.
In-hospital end point events included bleeding, hypotension
Abbreviations and Acronyms
aPTT 5 activated partial thromboplastin time
ASA 5 acetylsalicylic acid
CABG 5 coronary artery bypass graft surgery
COMPASS 5 Comparative Trial of Saruplase Versus Streptokinase
GUSTO 5 Global Utilization of Streptokinase and TPA [tissue-type
plasminogen activator] for Occluded Coronary Arteries
INJECT 5 International Joint Efficacy Comparison of
Thrombolytics trial
PTCA 5 percutaneous transluminal coronary angioplasty
TIMI 5 Thrombolysis in Myocardial Infarction
t-PA 5 tissue-type plasminogen activator
u-PA 5 urokinase-type plasminogen activator
Figure 1. Study protocol for the administration of trial medication. iv
(i.v.) 5 intravenous; po 5 oral.
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and allergic reactions. Patients were followed up for 1 year. To
determine possible antibody formation to the thrombolytic
medication, blood samples were taken before treatment, at
hospital discharge and at the 1-month follow-up visit. Analysis
was performed at Gru¨nenthal GmbH.
Data management and quality assurance. Patient data
were collected anonymously to retain confidentiality. All case
report forms were checked at monitoring visits for accuracy,
consistency and completeness on the basis of hospital files.
Audits were performed at randomly chosen centers.
Statistical analysis. The medical faculty of the University
of Bochum, Germany, Institute for Information Technology
and Biomathematics served as the study data and statistics
center. The trial was designed as an equivalence trial to test a
preformulated definition of the clinical equivalence of a saru-
plase regimen with that of the standard streptokinase regimen
on the basis of 30-day mortality rates. Equivalence was defined
as an odds ratio ,1.5 for all-cause mortality at 30 days for all
patients randomized. Using an alpha value of 0.05 (one-tailed),
a power of 80% and a generalized Fisher exact test, it was
calculated that 1,500 patients/treatment group would be nec-
essary. Because the study was adequately powered to detect
equivalence only by this a priori definition, no conclusions can
be drawn as to the superiority of saruplase in this respect.
Results
Patients. Between August 1992 and July 1994, a total of
3,089 patients were entered into the study at 104 hospitals in 12
countries: Austria (82 patients), Belgium (105 patients),
United Kingdom (252 patients), France (127 patients), Ger-
many (550 patients), Ireland (144 patients), Israel (332 pa-
tients), Italy (18 patients), The Netherlands (1,038 patients),
Portugal (20 patients), Russian Federation (177 patients) and
Spain (245 patients).
Two patients were inadvertently rerandomized within the
1-year study period after reinfarction and are considered only
as being treated once, according to the first enrollment. Data
up to 30 days were available for analysis in 3,088 (.99.9%) of
3,089 patients. The missing data were from a patient in the
streptokinase group who was considered for study purposes to
be survivor at 30 days.
The treatment groups were well matched at baseline (Ta-
bles 1 and 2). Only one baseline variable—age—differed (p ,
0.05) between the groups. The diagnosis of myocardial infarc-
tion was confirmed in 96.7% of patients according to World
Health Organization criteria of enzyme changes, symptoms
and electrocardiography. A history of previous myocardial
infarction was reported for 14.4% of patients (Table 2).
Study medications. The loading dose of ASA was admin-
istered in 95.6% of patients before the start of the study
therapy, and an additional 1.1% of patients had taken ASA
a few hours before admission. The intravenous heparin
(5,000 IU) or placebo bolus was administered to 99.1% of
patients. Infusion of the randomly assigned double-blind
thrombolytic agent was started in 99.4% of patients.
Intravenous heparin infusions, targeted to an activated
partial prothrombin time of 1.5 to 2.5 times normal levels, were
started in 99.0% of patients and continued for a median time
of 5 days in both treatment groups.
Intravenous nitrate infusion was started before lysis in
79.6% of patients. The prevalence of early concomitant ther-
apy was as follows (saruplase vs. streptokinase): 61.4% versus
62.6% for beta-adrenergic blocking agents; 27.8% versus 26.0%
for calcium channel blocking agents; and 30.7% versus 31.9%
for angiotensin-converting enzyme inhibitors, with no marked
difference in use between the groups.
Primary end point. Death from any cause up to 30 days
after randomization (primary study end point) occurred in 88
(5.7%) of 1,542 patients randomized to the saruplase group
and in 104 (6.7%) of 1,547 patients randomized to the strep-
tokinase group (odds ratio 0.84, p , 0.01 for equivalence)
(Table 3, Fig. 2). The median time to death in the saruplase
Table 1. Clinical Baseline Characteristics of Patients Receiving
Saruplase or Streptokinase
Saruplase
(n 5 1,542)
SK
(n 5 1,547)
90% CI of
Difference
p
Value
Age (yr) 59.3 (10.7) 60.4 (10.8) 21.7 to 20.5 0.004
Men 80.1% 79.3% 21.6 to 3.2
Height (cm) 171.0 (8.1) 170.8 (8.2) 20.3 to 0.7 0.582
Weight (kg) 76.9 (12.8) 77.1 (12.0) 21.0 to 0.6
Pulse rate (min21) 74.4 (17.0) 75.2 (16.9) 21.8 to 0.2 0.167
SBP (mm Hg) 134.1 (24.0) 134.6 (23.2) 21.9 to 0.9
DBP (mm Hg) 80.0 (13.6) 80.1 (13.4) 20.9 to 0.7
Killip class
I 85.2% 85.5%
II 12.9% 13.0%
III 1.1% 0.7%
IV 0.8% 0.7%
Time from Sx to
study Tx (min)
181 (83) 183 (82) 26.9 to 2.9
Data presented are mean (SD) or percent of patients. CI 5 confidence
interval; DBP 5 diastolic blood pressure; SBP 5 systemic blood pressure; SK 5
streptokinase; Sx 5 symptom; Tx 5 therapy.
Table 2. Comparability of Previous Medical History of Patients
Receiving Saruplase or Streptokinase at Randomization
Saruplase
(n 5 1,542)
SK
(n 5 1,547)
90% CI of
Difference
p
Value
Infarct site
AL 45.4% 47.2% 25.4 to 1.8
IP 54.4% 52.7% 21.9 to 5.3
MI confirmed 96.9% 96.6% 21.0 to 1.6
Prev MI 14.2% 14.7% 23.0 to 2.1
Prev lysis Tx 3.6% 2.8% 20.5 to 2.2 0.179
Diabetes 12.1% 10.6% 20.8 to 3.8 0.181
Hypertension 24.8% 25.0% 23.4 to 2.9
Angina 14.5% 13.5% 21.5 to 3.5
Current smoker 53.8% 49.6% 0.6 to 7.8 0.018
Data presented are percent of patients. AL 5 anterolateral; IP 5 infero-
posterior; MI 5 myocardial infarction; Prev 5 previous; other abbreviations as
in Table 1.
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treatment group was 2.4 days, and in that for the streptokinase
treatment group was 2.8 days. The main cause of death was
cardiogenic shock. The 1-year mortality rate was 8.2% (126 of
1,528) for saruplase treatment and 9.6% (147 of 1,530) for
streptokinase treatment.
Other clinical end points. Hypotension and cardiogenic
shock were more common in the streptokinase-treated patients
(Table 4). The incidence of arrhythmias and angina was similar
in the two treatment groups. The rate of reinfarction was
marginally higher in the saruplase treatment group and was
5.4% versus 4.5% at 30 days and 8.2% versus 7.1% at 1 year for
saruplase versus streptokinase. PTCA was performed in 11.3%
versus 10.3% of patients and CABG in 3.4% versus 3.9%
(saruplase vs. streptokinase) during the first 30 days.
There was no difference in bleeding rate between the
treatment groups. Severe bleeding was seldom seen, and the
need for transfusion was rare (Table 5).
The overall incidence of strokes (1.4% versus 1.4%) within
the first 30 days was similar to that in other trials in which
thrombolytic agents have been used (Table 6). Hemorrhagic
strokes occurred more often in the saruplase group (0.9%
versus 0.3%), whereas thromboembolic strokes were more
prevalent in the streptokinase group (0.5% versus 1.0%).
There was a slight tendency for more patients to die of stroke
after treatment with saruplase (13 of 22 versus 9 of 21). The
incidence of transient ischemic attacks was the same for both
groups. Additional strokes were reported from day 30 to 1 year
(1.1% versus 1.0%) and were mostly thromboembolic (0.7%
versus 0.5%) or unspecified (0.3% versus 0.3%).
Reactions that may have had an underlying allergic cause
were reported in 1.6% of saruplase-treated patients and in
4.1% of streptokinase-treated patients (p , 0.001). Severe
reactions were reported in two saruplase-treated patients (both
.3 days after treatment and not thought by the investigator to
be related to the trial medication) and 12 streptokinase-treated
patients (all within the first day and in 11 thought by the
investigator to be at least probably related to the trial medi-
cation). In .250 blood samples from saruplase-treated pa-
tients, no antibody was detected to saruplase or any possible
contaminating E. coli protein. All samples (both at discharge
and at 30 days) taken from the streptokinase-treated patients
demonstrated antibody formation.
Figure 2. One-year mortality rate. Kaplan-Meier curves for patients
randomized to receive saruplase (Sa [solid curve]) or streptokinase
(Sk [dashed curve]). CI 5 confidence interval.
Table 3. Causes of Death in Patients Receiving Saruplase
or Streptokinase
Saruplase
(n 5 1,542)
SK
(n 5 1,547)
90% CI of
Difference
p
Value
30-day mortality 88 (5.7%) 104 (6.7%) 22.8 to 0.8 0.242
1-yr mortality 126 (8.2%) 147 (9.6%) 23.4 to 0.7 0.193
Main cause of death at
30 days
Ventricular rupture/
tamponade
19 (21.6%) 7 (6.7%) 4.0 to 25.8 0.003
Cardiogenic shock 29 (33.0%) 44 (42.3%) 224.1 to 5.4 0.183
Ventricular
fibrillation/asystole
18 (20.5%) 28 (26.9%) 219.5 to 6.6 0.295
Stroke 10 (11.4%) 5 (4.8%) 22.3 to 15.4 0.092
Other 12 (13.6%) 20 (19.2%) 217.1 to 5.9 0.300
Data presented are number (%) of patients. Abbreviations as in Table 1.
Table 4. Cardiac Events up to 30 Days in Patients Receiving
Saruplase or Streptokinase
Saruplase
(n 5 1,542)
SK
(n 5 1,547)
90% CI of
Difference
p
Value
VF 99 (6.4%) 126 (8.1%) 23.6 to 0.2 0.065
VT 276 (17.9%) 275 (17.8%) 22.6 to 2.9
Bradycardia 340 (22.0%) 306 (19.8%) 20.7 to 5.2 0.121
Reinfarction 83 (5.4%) 69 (4.5%) 20.7 to 2.5 0.236
Pericarditis 56 (3.6%) 42 (2.7%) 20.4 to 2.2 0.146
Hypotension 484 (31.4%) 590 (38.1%) 210.2 to 23.3 0.001
Cardiogenic shock 51 (3.3%) 71 (4.6%) 22.7 to 0.2 0.067
Angina 426 (27.6%) 427 (27.6%) 23.2 to 3.2
Data presented are number (%) of patients. VF 5 ventricular fibrillation;
VT 5 ventricular tachycardia; other abbreviations as in Table 1.
Table 5. In-Hospital Bleeding Events (excluding stroke) in Patients
Receiving Saruplase or Streptokinase
Saruplase
(n 5 1,542)
SK
(n 5 1,547)
90% CI of
Difference
p
Value
Mild 160 (10.4%) 169 (10.9%) 22.8 to 1.7
Moderate 106 (6.9%) 109 (7.0%) 22.0 to 1.7
Severe 32 (2.1%) 38 (2.5%) 21.5 to 0.7 0.477
GI 14 9
Urogenital 1 2
Puncture site 12 20
Hb drop/anemia 5 7
Data presented are number or number (%) of patients. GI 5 gastrointesti-
nal; Hb 5 hemoglobin; other abbreviations as in Table 1.
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Discussion
Concomitant medication. The standard saruplase treat-
ment regimen includes a previous heparin bolus (5,000 IU) and
was shown in the Liquemin in Myocardial Infarction During
Thrombolysis With Saruplase (LIMITS) trial (6) to be associ-
ated with enhanced thrombolytic efficacy at no marked cost to
the safety of saruplase. Heparin placebo was given before
streptokinase because this is not the standard procedure for
streptokinase therapy (7). Therefore, the present study was a
comparison of two treatment regimens. Heparin was adminis-
tered to all patients after thrombolysis. This heparin regimen
was chosen because at the time of the study, heparin was
considered an important adjunctive therapy and was widely
used, and although not of proven use with streptokinase, it
appeared to be safe based on the Global Utilization of
Streptokinase and TPA for Occluded Coronary arteries
(GUSTO) study (8), albeit associated with a tendency for an
increased incidence of intracranial hemorrhage.
Primary end point, study size and statistics. Hospital
mortality rates after myocardial infarction have been declining
steadily over the past 20 years (9), and thrombolytic therapy
has certainly been a contributing factor. Among patients with
definite electrocardiographic ST segment elevation who pre-
sented early after symptom onset and were considered to be
eligible for thrombolytic therapy, a mortality rate of 6% to
10% at 1 month may be expected after streptokinase therapy
(4,8,10,11). To further lower this already low rate, any new
thrombolytic agent must be greatly superior to streptokinase.
In the GUSTO study (8), .40,000 patients were treated in four
study arms to eventually show a 1% increase in survival benefit
of t-PA over streptokinase. The tremendous consumption of
resources in these trials led to reluctance to develop new
thrombolytic drugs with a potentially more favorable safety/
efficacy relation. Innovative statistical designs to demonstrate
clinically defined equivalence, rather than superiority, are
gaining recognition by drug regulatory authorities as a way of
preventing this stagnation of thrombolytic drug research and
development.
The present study was a test of clinical equivalence, defined
as an odds ratio ,1.5 for the 30-day mortality rate after
treatment with saruplase or streptokinase. As in the Interna-
tional Joint Efficacy Comparison of Thrombolytics (INJECT)
study (4), it was presumed during the planning of the study that
there was a small mortality benefit over streptokinase. The
collaborators of the INJECT study performed a meta-analysis
of 13 placebo-controlled studies of thrombolysis showing a
mean mortality difference of 2.7% at 35 days. The lower limit
of the one-sided 95% confidence interval was 2.1%. In the
COMPASS study, the mortality difference (saruplase minus
streptokinase) was 21%, with a 95% confidence interval of
22.7% to 0.7%. Although the final study size was calculated on
an odds ratio of 1.5 (mortality under streptokinase 7%, al-
pha 5 5% and beta 5 20%), the results of the study showed an
odds ratio of 0.84. The upper limit of the one-sided 95%
confidence interval was 1.09%, and that for a one-sided 97.5%
confidence interval was 1.14%. Therefore, a placebo response
of .2% can be excluded. In the end, both the present and the
INJECT studies showed that the mortality rate for the new
thrombolytic agent was at least equivalent to that for strep-
tokinase.
Patency and mortality. A major breakthrough in compar-
ative thrombolysis trials was the confirmation of the open artery
hypothesis by the angiographic arm of the GUSTO study, in
which it was shown that early restoration of coronary artery
patency (Thrombolysis in Myocardial Infarction [TIMI] grade
3 angiographic perfusion) is a powerful predictor of survival at
30 days after thrombolysis (12,13). On this basis, the trend seen
in the present study to lower mortality in the saruplase group
(5.7%) compared with the streptokinase group (6.7%) is
reinforced by the results of a previous coronary artery patency
trial comparing saruplase therapy with streptokinase (3). In the
double-blind Prourokinase in Myocardial Infarction trial
(PRIMI) trial of 401 patients, patency (TIMI grade 2 or 3
angiographic flow) was more rapidly restored with saruplase
than with streptokinase. At 60 min after the start of therapy,
the patency rate was 48.0% for patients in the streptokinase
group versus 71.8% for patients in the saruplase group (p ,
0.001); by 90 min, the respective patency rates were 63.9% and
71.2%, respectively (p 5 0.15).
The high patency rates with low reocclusion rates have been
confirmed in a study of saruplase versus alteplase (14). The
90-min patency rates were 80% for patients receiving saruplase
and 81% for patients receiving alteplase, with reocclusion rates
of 1.2% and 2.4%, respectively.
It is very probable that the trend to lower mortality rates in
the saruplase group in the COMPASS trial is indeed real. The
primary study end point was achieved because the standard
saruplase regimen was proved to be at least clinically equiva-
lent to streptokinase (p , 0.001) in terms of 30-day survival
rates. In comparing the reference (streptokinase) group out-
comes with those from other randomized trials, a comparable
30-day mortality rate was seen in the GUSTO trial (8) (7.4%
for the streptokinase group with intravenous heparin versus
6.7% in the COMPASS trial), but a slightly higher rate (9.5%)
occurred in the INJECT trial (4).
Table 6. Strokes and Transient Ischemic Attacks at 30 Days in
Patients Receiving Saruplase or Streptokinase
Saruplase
(n 5 1,542)
SK
(n 5 1,547)
90% CI of
Difference
p
Value
TIA 7 (0.5%) 8 (0.5%) 20.6 to 0.5
All strokes 22 (1.4%) 21 (1.4%) 20.8 to 1.0 0.870
Hemorrhagic 14 (0.9%) 5 (0.3%) 20.0 to 1.2 0.038
Thromboembolic 8 (0.5%) 15 (1.0%) 21.1 to 0.2 0.145
Unclassified 0 (0.0%) 1 (0.1%) 20.3 to 0.1
Outcome of stroke
Death up to 30 days 13 (0.9%) 9 (0.6%) 20.4 to 0.9
Disabling 5 (0.3%) 6 (0.4%) 20.5 to 0.4
No deficit 5 (0.3%) 7 (0.4%) 20.6 to 0.4
Data presented are number (%) of patients. Abbreviations as in Table 1.
491JACC Vol. 31, No. 3 TEBBE ET AL.
March 1, 1998:487–93 COMPASS TRIAL OF SARUPLASE VS. STREPTOKINASE
Strokes. From a clinical perspective, treatment with saru-
plase is at least equivalent and tends toward a 15% relative
reduction in mortality compared with streptokinase therapy.
Because this is all-cause mortality, it already includes a possi-
ble increase in fatal hemorrhagic strokes, which arguably may
be related to an increased thrombolytic efficacy itself. Due to
the increased rate of severe nonfatal hemorrhagic strokes
possibly associated with the more efficacious thrombolytic
regimens, it has been argued that a more revealing outcome
variable is the combined end point of death or disabling stroke.
Disabling stroke is defined as stroke that results in a patient
who is no longer able of looking after himself or herself, which
could have an economic impact. The number of disabling
strokes was almost the same in both treatment groups, and
there is therefore no change in the trend seen with the
mortality data in favor of saruplase. Stroke rates overall were
similar between the two treatment groups, but there is a
distinct trend in the saruplase treatment group toward a lower
incidence of thromboembolic strokes and a higher incidence of
hemorrhagic strokes than with the streptokinase group. Spec-
ulative stroke classification was avoided; only when computer
tomography or an autopsy was performed and the etiology was
confirmed was a classification made. Others are termed “un-
classified.” Hemorrhagic stroke rates for streptokinase have
been reported of 0.1% to 0.5% (8,10,11,15,16), and for throm-
boembolic strokes, the rates are 0.7% to 1.3%. Therefore, the
results with streptokinase in this study are in broad agreement
with the published data.
Although the precise mechanism of action of saruplase is
not known, ;30% of the dose administered in the regimen
used in this study is converted to two-chain u-PA (17), which
probably contributes significantly to lysis and side effects.
Allergic-type reactions. A number of possible allergic re-
actions were reported in patients treated with saruplase, but no
antibody directed toward saruplase was detected; these reac-
tions could be attributed to other procedures or medications,
such as ASA. All samples taken from patients administered
streptokinase demonstrated antibody formation, and the inci-
dence of both severe and other allergic-type reactions was
much higher than that for the saruplase-treated group.
Conclusions. The present study demonstrated that the
30-day mortality rate for saruplase treatment is at least equiv-
alent to that for streptokinase treatment, with an overall stroke
rate and outcome after stroke that appear to be similar for the
two treatments.
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